Page last updated: 2024-10-17

phosphonoacetic acid and Herpes Genitalis

phosphonoacetic acid has been researched along with Herpes Genitalis in 15 studies

Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.

Herpes Genitalis: Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.

Research Excerpts

ExcerptRelevanceReference
"A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection."9.06Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986)
"Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0."9.06Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987)
"The activity of phosphonoacetic acid (PAA) and phosphonoformic acid (PFA) against four strains of herpes simplex virus type 1 (HSV-1) and four strains of HSV-2 were compared in tissue culture and in a murine model of genital herpes."7.66A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice. ( Glasgow, LA; Kern, ER; Overall, JC; Richards, JT, 1981)
"Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42."6.67A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991)
"Treatment with foscarnet cream was not associated with any significant side effects."6.66Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. ( Doraisingham, S; Lee, CT; Lim, KB; Ling, AE; Tan, T; Thirumoorthy, T, 1986)
"Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1."6.66Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985)
"A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection."5.06Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986)
"Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0."5.06Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987)
"In an AIDS patient who had repeated successful treatment with acyclovir in his history, erosive herpes perianalis with herpes proctitis appeared, which persisted over several weeks."3.68[Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS]. ( Bratzke, B; Ehlers, G; Orfanos, CE; Stavermann, T, 1991)
"The activity of phosphonoacetic acid (PAA) and phosphonoformic acid (PFA) against four strains of herpes simplex virus type 1 (HSV-1) and four strains of HSV-2 were compared in tissue culture and in a murine model of genital herpes."3.66A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice. ( Glasgow, LA; Kern, ER; Overall, JC; Richards, JT, 1981)
"Topical treatment of herpes genitalis in female guinea pigs with 2-deoxy-D-glucose in either agarose gels or miconazole nitrate ointments failed to prevent the development of genital lesions or to reduce the mean titers of recoverable virus in vaginal swabs from infected animals."3.66Lack of efficacy of 2-deoxy-D-glucose in the treatment of experimental herpes genitalis in guinea pigs. ( Arnett, G; Drennen, DJ; Shannon, WM, 1982)
"Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42."2.67A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991)
"Treatment with foscarnet cream was not associated with any significant side effects."2.66Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. ( Doraisingham, S; Lee, CT; Lim, KB; Ling, AE; Tan, T; Thirumoorthy, T, 1986)
"Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1."2.66Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985)
"The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem."2.36[Herpes simplex]. ( Fanta, D, 1981)
" In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg."1.27Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines. ( Hsiung, GD; Mayo, DR, 1984)
"Using a guinea pig model of genital herpes simplex virus (HSV) type 2 infection, phosphonoformate treatment initiated after the onset of symptoms had a therapeutic effect on the outcome of disease."1.27Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs. ( Hsiung, GD; Lucia, HL; Mayo, DR, 1983)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-199011 (73.33)18.7374
1990's4 (26.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mayo, DR2
Hsiung, GD2
Kern, ER1
Richards, JT1
Overall, JC1
Glasgow, LA1
Fanta, D1
Lucia, HL1
Shannon, WM1
Arnett, G1
Drennen, DJ1
Li, YY1
Minagawa, H1
Tanaka, S1
Mori, R1
Safrin, S1
Crumpacker, C1
Chatis, P1
Davis, R1
Hafner, R1
Rush, J1
Kessler, HA1
Landry, B1
Mills, J1
Bratzke, B1
Orfanos, CE1
Stavermann, T1
Ehlers, G1
Spitzbart, H1
Seyffert, C1
Thust, U1
Chatis, PA1
Miller, CH1
Schrager, LE1
Crumpacker, CS1
Youle, MM1
Hawkins, DA1
Collins, P1
Shanson, DC1
Evans, R1
Oliver, N1
Lawrence, A1
Barton, SE1
Munday, PE1
Kinghorn, GR1
van der Meijden, WI1
Stolz, E1
Notowicz, A1
Rashid, S1
Schuller, JL1
Essex-Cater, AJ1
Kuijpers, MH1
Sacks, SL1
Portnoy, J1
Lawee, D1
Schlech, W1
Aoki, FY1
Tyrrell, DL1
Poisson, M1
Bright, C1
Kaluski, J1
Lim, KB1
Doraisingham, S1
Thirumoorthy, T1
Lee, CT1
Ling, AE1
Tan, T1
Wallin, J1
Lernestedt, JO1
Ogenstad, S1
Lycke, E1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985]Phase 326 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for phosphonoacetic acid and Herpes Genitalis

ArticleYear
[Herpes simplex].
    Wiener klinische Wochenschrift, 1981, Dec-25, Volume: 93, Issue:24

    Topics: Adolescent; Adult; Amantadine; Antigens, Viral; Cell Transformation, Viral; Female; Foscarnet; Herpe

1981

Trials

5 trials available for phosphonoacetic acid and Herpes Genitalis

ArticleYear
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
    The New England journal of medicine, 1991, Aug-22, Volume: 325, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial;

1991
Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
    Genitourinary medicine, 1986, Volume: 62, Issue:4

    Topics: Administration, Topical; Clinical Trials as Topic; Double-Blind Method; Female; Foscarnet; Herpes Ge

1986
Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.
    The Journal of infectious diseases, 1987, Volume: 155, Issue:2

    Topics: Administration, Topical; Adolescent; Adult; Antiviral Agents; Clinical Trials as Topic; Double-Blind

1987
Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes.
    Annals of the Academy of Medicine, Singapore, 1986, Volume: 15, Issue:4

    Topics: Administration, Topical; Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Double

1986
Topical treatment of recurrent genital herpes infections with foscarnet.
    Scandinavian journal of infectious diseases, 1985, Volume: 17, Issue:2

    Topics: Administration, Topical; Adult; Clinical Trials as Topic; Double-Blind Method; Erythema; Female; Fos

1985

Other Studies

9 other studies available for phosphonoacetic acid and Herpes Genitalis

ArticleYear
Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines.
    Antimicrobial agents and chemotherapy, 1984, Volume: 26, Issue:3

    Topics: Acyclovir; Animals; Antiviral Agents; Arabinofuranosyluracil; Cytarabine; Female; Foscarnet; Guinea

1984
A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice.
    Antiviral research, 1981, Volume: 1, Issue:4

    Topics: Animals; Antiviral Agents; Drug Evaluation, Preclinical; Female; Foscarnet; Ganglia, Spinal; Herpes

1981
Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs.
    Intervirology, 1983, Volume: 19, Issue:1

    Topics: Animals; Antiviral Agents; Drug Evaluation, Preclinical; Female; Foscarnet; Ganglia, Spinal; Guinea

1983
Lack of efficacy of 2-deoxy-D-glucose in the treatment of experimental herpes genitalis in guinea pigs.
    Antimicrobial agents and chemotherapy, 1982, Volume: 21, Issue:3

    Topics: Administration, Topical; Animals; Deoxy Sugars; Deoxyglucose; Female; Guinea Pigs; Herpes Genitalis;

1982
Suppression of infectious virus spread to the liver by foscarnet following lethal infection of acyclovir-resistant herpes simplex virus type 2 in mice.
    Antiviral research, 1995, Volume: 27, Issue:1-2

    Topics: Acyclovir; Animals; Arabinonucleosides; Brain; Chlorocebus aethiops; Drug Resistance, Microbial; Fos

1995
[Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1991, Volume: 42, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Dose-Response Relationship,

1991
[Triapten ointment in the treatment of herpes genitalis in the female].
    Zentralblatt fur Gynakologie, 1990, Volume: 112, Issue:17

    Topics: Antiviral Agents; Female; Foscarnet; Herpes Genitalis; Humans; Ointments; Phosphonoacetic Acid; Uter

1990
Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
    The New England journal of medicine, 1989, Feb-02, Volume: 320, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial;

1989
Acyclovir-resistant herpes in AIDS treated with foscarnet.
    Lancet (London, England), 1988, Aug-06, Volume: 2, Issue:8606

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet;

1988